-
1 Comment
Ginwa Enterprise (Group) Inc is currently in a long term uptrend where the price is trading 17.7% above its 200 day moving average.
From a valuation standpoint, the stock is 65.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Ginwa Enterprise (Group) Inc's total revenue sank by 1.9% to $195M since the same quarter in the previous year.
Its net income has increased by 22.7% to $20M since the same quarter in the previous year.
Finally, its free cash flow fell by 40.1% to $10M since the same quarter in the previous year.
Based on the above factors, Ginwa Enterprise (Group) Inc gets an overall score of 3/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE000000QQ8 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Target Price | None |
|---|---|
| Beta | 0.26 |
| Dividend Yield | 0.4% |
| Market Cap | 3B |
| PE Ratio | 34.14 |
Ginwa Enterprise (Group) Inc. researches, develops, produces, markets, and sells traditional Chinese medicines, biological drugs, and chemical drugs primarily in China. The company offers a range of orthopaedics, immunity, children, and general medicines in various dosage forms, including tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions. It is also involved in the pharmaceutical logistics activities. The company was founded in 1996 and is headquartered in Xi'an, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600080.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
